In the case of TNBC, nanobodies against tumor-specific antigens such as TNF-α, EGFR, CD3, CTLA-4, STAT-3, AKT2 among others, have been generated and tested for targeting cancer cells (22). The gene discussed is EGFR; the disease is cancer.